Johns Hopkins Medicine

Running trials

• Recruiting

  Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

  NCT07521930· Johns Hopkins University· Source

• Recruiting

  Multimodal Glucose Prediction in Type 2 Diabetes

  NCT07633171· Johns Hopkins University· Source

• Recruiting

  A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

  NCT07559175· Phase 2· Aimmune Nestlé Health Science US R&D, LLC· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Recruiting

  Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine

  NCT07223008· Johns Hopkins University· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07210723· Phase 2/3· Kardigan, Inc.· Source

• Active, not recruiting

  A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

  NCT05154487· Phase 2· GOG Foundation· Source

• Active, not recruiting

  XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)

  NCT05881278· XVIVO Perfusion· Source

• Active, not recruiting

  CTSN Embolic Protection Trial

  NCT06027788· Icahn School of Medicine at Mount Sinai· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Recruiting

  A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05372354· Phase 1/2· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

  NCT05123703· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Investigation on the Cortical Communication (CortiCom) System

  NCT03567213· Johns Hopkins University· Source

• Active, not recruiting

  NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors

  NCT04656496· University of South Florida· Source

• Active, not recruiting

  Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

  NCT02766543· Profound Medical Inc.· Source

• Recruiting

  Blue Light Cystoscopy With Cysview® Registry

  NCT02660645· Photocure· Source

• Enrolling by invitation

  Genetic Modifiers of Cystic Fibrosis Related Diabetes

  NCT01113216· Johns Hopkins University· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• ALS (motor neurone disease)2 recruiting
• Cystic fibrosis2 recruiting
• Dilated cardiomyopathy2 recruiting
• Stroke2 recruiting
• Bladder cancer1 recruiting
• Migraine1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Spinal cord injury1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

  NCT06793397· Phase 3· Cybin IRL Limited· Source

• Completed

  HEARS-SLP: Providing SLP-Delivered Hearing Health Care to Individuals With Cognitive Impairment

  NCT06008782· Johns Hopkins University· Source

• Completed

  Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

  NCT05794139· Phase 2· NMD Pharma A/S· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  Environmental Localization Mapping and Guidance for Visual Prosthesis Users

  NCT04359108· Johns Hopkins University· Source

• Completed

  A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

  NCT04229004· Phase 3· Pancreatic Cancer Action Network· Source

• Completed

  Instrumented Data Exchange for Ataxia Study

  NCT04268147· University of Chicago· Source

• Completed

  Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)

  NCT03568994· Early phase 1· Baylor College of Medicine· Source

• Completed

  Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer

  NCT03375489· Massachusetts General Hospital· Source

• Completed

  Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

  NCT03309111· Phase 1· Ichnos Sciences SA· Source

• Completed

  The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

  NCT01566695· Phase 3· Celgene· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke253 works · 3 trials
• HIV205 works · 0 trials
• Alzheimer disease195 works · 0 trials
• Obesity156 works · 1 trial
• Heart failure140 works · 1 trial
• Prostate cancer112 works · 1 trial
• Tuberculosis95 works · 0 trials
• Type 2 diabetes86 works · 1 trial
• Pancreatic cancer79 works · 1 trial
• Chronic kidney disease72 works · 0 trials
• Multiple sclerosis69 works · 1 trial
• Schizophrenia66 works · 0 trials
• Parkinson disease65 works · 0 trials
• Epilepsy65 works · 0 trials
• Melanoma64 works · 0 trials
• Bladder cancer57 works · 1 trial
• Cystic fibrosis57 works · 2 trials
• Atrial fibrillation56 works · 0 trials
• Asthma53 works · 0 trials
• Hearing loss51 works · 1 trial
• Glioblastoma49 works · 0 trials
• Sarcoma43 works · 0 trials
• Glaucoma42 works · 0 trials
• ALS (motor neurone disease)36 works · 2 trials
• Kidney cancer34 works · 0 trials
• Bipolar disorder32 works · 0 trials
• COPD32 works · 0 trials
• Macular degeneration29 works · 0 trials
• Hepatitis C28 works · 0 trials
• Sickle cell disease28 works · 0 trials